1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)

Table 5:

Base case and scenario analyses

StrategyCostIncremental Cost ($)Effectiveness (QALYs)Incremental EffectivenessIncremental Cost-EffectivenessICER
Base case
    CEA$24,6246.833605
    CAS$30,731$6107.006.71−0.124580Dominateda
SAPPHIRE
    CEA$77,377$14,801.485.14−1.9615049Dominateda
    CAS$62,5767.18814
EVA-3S
    CEA$225856.82$3312
    CAS$30,832$8246.386.67−0.15$4695Dominateda
CREST
    CEA$22,2596.89$3227
    CAS$25,846$3587.006.63−0.27$3900Dominateda
  • Note:—ICER indicates incremental cost-effectiveness ratio.

  • a “Dominated” means that the treatment modality was associated with more cost and less effectiveness.